OIPE JC56
MAY 18 2004
PATENT & TRADEMARK OFFICE

IDS

PTO/SB/21 (08-03)

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/681,858
		Filing Date	October 7, 2003
		First Named Inventor	Piomelli, Daniele
		Art Unit	1614
		Examiner Name	To Be Assigned
Total Number of Pages in This Submission	6	Attorney Docket Number	02307E-127510US

ENCLOSURES ***(Check all that apply)***

☐ Fee Transmittal Form	☐ Drawing(s)	☐ After Allowance Communication to Group
☐ Fee Attached	☐ Licensing-related Papers	☐ Appeal Communication to Board of Appeals and Interferences
☐ Amendment/Reply	☐ Petition	☐ Appeal Communication to Group (**Appeal Notice, Brief, Reply Brief**)
☐ After Final	☐ Petition to Convert to a Provisional Application	☐ Proprietary Information
☐ Affidavits/declaration(s)	☐ Power of Attorney, Revocation Change of Correspondence Address	☐ Status Letter
☐ Extension of Time Request	☐ Terminal Disclaimer	☒ Other Enclosure(s) *(please identify below)*:
☐ Express Abandonment Request	☐ Request for Refund	References (21); Return Postcard.
☒ Information Disclosure Statement	☐ CD, Number of CD(s)	
☐ Certified Copy of Priority Document(s)		
☐ Response to Missing Parts/ Incomplete Application		
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Frank J. Mycroft Reg. No. 46,946
Signature	
Date	May 4, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Jose Luna		
Signature		Date	May 4, 2004

60174566 v1

OIPE
MAY 18 2004
PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 4, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: _____

PATENT
Attorney Docket No.: 02307E-127510US
Client Reference No.: 2001-104-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniele Piomelli, et al.

Application No.: 10/681,858

Filed: October 7, 2003

For: MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS

Examiner: To Be Assigned

Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with the Office's waiver, issued in the August 5, 2003 Official Gazette, copies of the cited U.S. patent publications are not enclosed. Copies of all other references are submitted herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:jvl
60174555 v1

OIPE JC/SF
MAY 18 2004
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/681,858
Filing Date	October 7, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	02307E-127510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number: Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	6,096,784 A	08-01-2000	Lerner et al.	
	2.	6,271,015 B1	08-07-2001	Gilula et al.	
	3.	6,326,156 B1	12-04-2001	Civelli et al.	
	4.	6,359,010 B1	03-19-2002	Geracioti, Jr. et al.	
	5.	6,562,846 B2	05-13-2003	Sit et al.	
	6.	2002/0187542 A1	12-12-2002	Gilula et al.	
	7.	2002/0188009 A1	12-12-2002	Sit et al.	
	8.	2003/0149082 A1	08-07-2003	Makriyannis et al.	
	9.	2003/0195226 A1	10-16-2003	Sit et al.	
	10.	USSN 60/336,289	N/A (Filed 10-31-2001)	Piomelli et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	11.	WO	98/24396	A2	06-11-1998	Neurosci. Res. Found.		☐
	12.	WO	03/065989	A2	08-14-2003	Bristol-Myers		☐
								☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/681,858
				Filing Date	October 7, 2003
				First Named Inventor	Piomelli, Daniele
				Art Unit	1614
(use as many sheets as necessary)				*Examiner Name*	To Be Assigned
Sheet	2	of	3	*Attorney Docket Number*	02307E-127510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	13.	BARNETT-NORRIS, J. et al., "Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor" J. Med. Chem. 451:3649-3659 (2002).	
	14.	BELTRAMO, M. et al., "Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one" FEBS Lett. 403:263-267 (1997).	
	15.	BISOGNO, T. et al., "Fatty acid amide hydrolase, an enzyme with many bioactive substrates. possible therapeutic implications" Curr. Pharm. Des. 8:533-547 (2002).	
	16.	BOGER, D. et al., "Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anadamide" Proc. Natl. Acad. Sci. USA 97:5044-5049 (2000).	
	17.	BRACEY, M. et al., "Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling" Science 298:1793-1796 (2002).	
	18.	CRAVATT, B. et al., "Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase" Proc. Natl. Acad. Sci. USA 98:9371-9376 (2001).	
	19.	DE PETROCELLIS, L. et al., "Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase" Biochem. Biophys. Res. Commun. 231:82-88 (1997).	
	20.	DEUTSCH, D. et al., "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor" Biochem. Biophys. Res. Commun. 231:217-221 (1997).	
	21.	DINH, T. et al., "Brain monoglyceride lipase participating in endocannabinoid inactivation" Proc. Natl. Acad. Sci. USA 99:10819-10824 (2002).	
	22.	KATHURIA, S. et al., "Modulation of anxiety through blockade of anandamide hydrolysis" Nature Medicine 9(1):76-81 (2003).	
	23.	KOUTEK, B. et al., "Inhibitors of arachidonoyl ethanolamide hydrolysis" J. Biol. Chem. 269:22937-22940 (1994).	
	24.	LOPEZ-RODRIGUEZ, M., et al., "Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase" J. Med. Chem. 46:1512-1522 (2003).	
	25.	PIOMELLI, D. et al., "The endocannabinoid system as a target for therapeutic drugs" Trends Pharmacol. Sci. 21:218-224 (2000).	
	26.	QUISTAD, G. et al., "Fatty acid hydrolase inhibition by neurotoxic organophosphorus pesticides" Toxicology and Applied Pharmacology 173:48-55 (2001).	
	27.	REGGIO, P. et al., "Conformational requirements for endocannabinoid interaction with the cannabinoid receotirs, the anandamide transporter and fatty acid amidohydrolase" Chem. Phys. Lipids 108:15-35 (2000).	
	28.	SMITH, A., "Endocannabinoid System: FAAH better anxiolytics?" Nat. Rev. Drug Discov. 2:92 (2003).	
	29.	TARZIA, G. et al., "Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors" J. Med. Chem. 46:2352-2360 (2003).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(use as many sheets as necessary)* Sheet 3 of 3	*Complete if Known*	
	Application Number	10/681,858
	Filing Date	October 7, 2003
	First Named Inventor	Piomelli, Daniele
	Art Unit	1614
	Examiner Name	To Be Assigned
	Attorney Docket Number	02307E-127510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	30.	WENDELER, M. et al., "Inhibitors of endocannabinoid degradation: potential therapeutics for neurological disorders" Angew. Chem. Int. Ed. 42:2938-2941 (2003).	

60174555 v1

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.